I-Mab IMAB Stock
I-Mab Price Chart
I-Mab IMAB Financial and Trading Overview
I-Mab stock price | 0.73 USD |
Previous Close | 3.08 USD |
Open | 3.08 USD |
Bid | 3.09 USD x 1800 |
Ask | 3.1 USD x 900 |
Day's Range | 2.99 - 3.17 USD |
52 Week Range | 2.73 - 12.76 USD |
Volume | 345.34K USD |
Avg. Volume | 347.32K USD |
Market Cap | 256.99M USD |
Beta (5Y Monthly) | 0.97191 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -2.42 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 34.5 USD |
IMAB Valuation Measures
Enterprise Value | -3105556224 USD |
Trailing P/E | N/A |
Forward P/E | -2.095238 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | -1.159915 |
Price/Book (mrq) | 0.08496786 |
Enterprise Value/Revenue | 14.017 |
Enterprise Value/EBITDA | 1.67 |
Trading Information
I-Mab Stock Price History
Beta (5Y Monthly) | 0.97191 |
52-Week Change | -69.95% |
S&P500 52-Week Change | 19.24% |
52 Week High | 12.76 USD |
52 Week Low | 2.73 USD |
50-Day Moving Average | 3.23 USD |
200-Day Moving Average | 4.15 USD |
IMAB Share Statistics
Avg. Volume (3 month) | 347.32K USD |
Avg. Daily Volume (10-Days) | 228.55K USD |
Shares Outstanding | 83.1M |
Float | 38.28M |
Short Ratio | 5.78 |
% Held by Insiders | 0.75% |
% Held by Institutions | 64.05% |
Shares Short | 1.55M |
Short % of Float | N/A |
Short % of Shares Outstanding | 1.85% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | December 31, 2022 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | 845.79% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -24.21% |
Return on Equity (ttm) | -63.73% |
Income Statement
Revenue (ttm) | -221563008 USD |
Revenue Per Share (ttm) | -2.685 USD |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | N/A |
EBITDA | -1859417984 USD |
Net Income Avi to Common (ttm) | -2411822080 USD |
Diluted EPS (ttm) | -4.4 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 3.45B USD |
Total Cash Per Share (mrq) | 41.56 USD |
Total Debt (mrq) | 74.99M USD |
Total Debt/Equity (mrq) | 2.49 USD |
Current Ratio (mrq) | 5.497 |
Book Value Per Share (mrq) | 36.249 |
Cash Flow Statement
Operating Cash Flow (ttm) | N/A |
Levered Free Cash Flow (ttm) | N/A |
Profile of I-Mab
Country | United States |
State | N/A |
City | Shanghai |
Address | New Bund Center |
ZIP | 200124 |
Phone | 86 21 6057 8000 |
Website | https://www.i-mabbiopharma.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | N/A |
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting growth hormone, which has completed Phase 3 clinical trials to treat pediatric growth hormone deficiency; Efineptakin alfa, a recombinant human IL-7 that is in Phase 2 for cancer treatment-related lymphopenia and cancer immunotherapy; and Lemzoparlimab, a CD47 monoclonal antibody that has completed Phase 2 clinical trial. Its product candidates also includes TJ210, a monoclonal antibody against human C5aR1 that is in Phase 1 for the treatment of cancers and autoimmune; Uliledlimab, a CD73 antibody, which is in Phase 2 clinical trials for treating solid tumors and oncology; TJ-L14B, a PD-L1-based tumor-dependent T-cell engager for solid cancers; Givastomig, a tumor-dependent T cell engager for gastric and other cancers; TJ-L1IF, a PD-L1/IFN-a antibody-cytokine fusion protein for PD(L)-1 resistant tumors; and TJ-C64B, a bispecific antibody for ovarian and other cancers. The company has strategic collaboration agreement with PT Kalbe Genexine Biologics; AbbVie Ireland Unlimited Company; Jumpcan Pharmaceutical Group; Sinopharm Group Co. Ltd.; and Roche Diagnostics. I-Mab was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Q&A For I-Mab Stock
What is a current IMAB stock price?
I-Mab IMAB stock price today per share is 0.73 USD.
How to purchase I-Mab stock?
You can buy IMAB shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for I-Mab?
The stock symbol or ticker of I-Mab is IMAB.
Which industry does the I-Mab company belong to?
The I-Mab industry is Biotechnology.
How many shares does I-Mab have in circulation?
The max supply of I-Mab shares is 81.5M.
What is I-Mab Price to Earnings Ratio (PE Ratio)?
I-Mab PE Ratio is now.
What was I-Mab earnings per share over the trailing 12 months (TTM)?
I-Mab EPS is -2.42 USD over the trailing 12 months.
Which sector does the I-Mab company belong to?
The I-Mab sector is Healthcare.
I-Mab IMAB included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
NASDAQ Golden Dragon China Inde HXC | 7550 USD — |
-1.9
|
— — | 7498.89 USD — | 7612.35 USD — | — - | — — |
NASDAQ Global Market Composite NQGM | 1737.75 USD — |
-6
|
— — | 1724.84 USD — | 1770.8 USD — | — - | — — |
NASDAQ Biotechnology NBI | 4130.78 USD — |
-1.87
|
— — | 4123.5 USD — | 4185.42 USD — | — - | — — |
NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
- {{ link.label }} {{link}}